** Shares of Cochlear COH.AX fall as much as 1.3% to A$309.090
** Shares of the healthcare technology co set for their weakest week since December 9, 2024, if losses hold
** The priciest stock in ASX is tracking losses seen by the country's healthcare sub-index .AXHJ, which is down 0.7%
** UBS hikes stock's price target to A$270 from A$265, retains "sell" rating
** Brokerage made changes to their foreign exchange estimates, underlying assumptions are unchanged
** Three of 15 analysts rate the stock "buy" or higher, 10 "hold" and two "sell"; their median PT is A$305.00 – LSEG data
** Stock fell 8.8% in 2024
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。